+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura



Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura



Blood 84(10 Suppl. 1): 700A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 030808391

Download citation: RISBibTeXText


Related references

Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis 73(1): 10-14, 1995

Native form and truncated form of tissue factor pathway inhibitor in patients with thrombotic thrombocytopenic purpura and disseminated intra-vascular coagulation. Blood 86(10 Suppl. 1): 927A, 1995

Prospective study of the effect of plasma exchange on von Willebrand factor cleaving protease and autoantibody inhibitor levels in thrombotic thrombocytopenic purpura. Blood 98(11 Part 1): 754a, 2001

Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clinical and Applied Thrombosis/Hemostasis 7(3): 229-233, 2001

Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. Journal of Clinical Apheresis 30(1): 50-54, 2015

The Effect of Plasma Exchange Therapy on von Willebrand Factor Cleaving Protease Activity of ADAMTS13 and on Autoantibody Inhibitor Levels in Index Episodes and Relapses of Thrombotic Thrombocytopenic Purpura. Blood 100(11): Abstract No 2705, 2002

Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thrombosis Research 119(4): 447-452, 2007

Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. British Journal of Haematology 162(6): 819-826, 2013

Plasma levels of Tissue Factor Pathway Inhibitor are decreased in the coronary sinus of patients with acute myocardial infarction. European Heart Journal 20(ABSTR Suppl. ): 194, 1999

Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). American Journal of Hematology 53(4): 213-220, 1996

Increased platelet residual activity in patients treated with acetosalicylic acid is associated with increased tissue factor and decreased tissue factor pathway inhibitor plasma levels. International Journal of Cardiology 146(3): 479-481, 2011

Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange. Journal of Clinical Apheresis 16(4): 179-185, 2001

Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation. Blood Coagulation and Fibrinolysis 8(6): 345-349, 1997

Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa. Transfusion and Apheresis Science 58(1): 72-78, 2019

Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood 53(2): 333-338, 1979